Prospective non-interventional cohort study to assess safety and tolerability of 3Fluart 2019/2020 trivalent seasonal influenza vaccine in children, adolescent, adults and elderly subjects (3Fluart-H-27)

First published: 23/05/2019
Last updated: 17/04/2024

Study | Finalised

Administrative details

PURI
https://redirect.ema.europa.eu/resource/34741

EU PAS number
EUPAS29839

Study ID
34741

DARWIN EU® study
No

Study countries
Hungary

Study description
The aim is this observational study, which will be initiated right after 3Fluart 2019/202 seasonal influenza vaccine is licensed and used in a mass vaccination campaign, is to detect a potential increase in reactogenicity and allergic events that is intrinsic to the product in near real-time aiming to mitigate risks before the peak period of seasonal immunisation. The objectives are to evaluate the occurrence of defined Adverse Events of

Interests (AEIs) and other Adverse Events (AEs) in vaccinated subjects participating in the study and to rapidly detect any clinically significant change compared to what was known or expected with the previous vaccine compositions in the frequency and severity of Adverse Reactions (ARs) in vaccinated subjects participating in the study. Defined cohorts of children and adults will be actively followed-up seven (7) days after immunisation for AEIs and other AEs following vaccination, with the aim to detect eventual changes in the frequency an severity of related events. Patients will be vaccinated according to the Summary of Product Characteristics (SmPC), in compliance with national vaccination policy decisions in Hungary and standard consent and forms. Relevant inforamtion on AEs will be collected during a follow-up phone contact seven (7) days after vaccination. The duration of the study on a patient basis will be seven (7) days. The study will be conducted in multiple study centres in Hungary. A maximum of six hundred (600) and a minimum of five hundred (500) male and female subjects will be vaccinated with 3Fluart vaccine containing influenza virus strains recommended for the 2019/2020 seasonal epidemics in accordance with the SmPC and involved into the study according to Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU.

Study status
Finalised

Research institution and networks

Institutions

Gyermek Háziorvosi Rendel?
First published: 01/02/2024
Last updated 01/02/2024
Institution

Multiple centres: 10 centres are involved in the study

Contact details

Study institution contact
Orsolya Gyurján
Study contact

orsolya.gyurjan@fluart.hu
Primary lead investigator

Gábor Hacsek
Primary lead investigator

Study timelines

Date when funding contract was signed
Planned:
31/05/2019
Actual:
31/05/2019

Study start date
Planned:
01/10/2019
Actual:
14/10/2019

Data analysis start date
Planned:
08/10/2019
Actual:
21/10/2019

Date of interim report, if expected
Planned:
01/11/2019
Actual:
14/11/2019

Date of final study report
Planned:
01/06/2019
Actual:
20/03/2020

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Fluart Innovative Vaccines Ltd.

Study protocol

3Fluart-H-27_Vizsgálati terv_v01_20190528.pdf(5.63 MB)

Regulatory

Was the study required by a regulatory body?
Yes

Is the study required by a Risk Management Plan (RMP)?
EU RMP category 3 (required)

Methodological aspects

Study type

Study type list

Study topic:
Human medicinal product

Study type:
Non-interventional study

Scope of the study:
Assessment of risk minimisation measure implementation or effectiveness
Disease epidemiology

Data collection methods:
Combined primary and secondary data collection

Main study objective:
To detect a potential increase in reactogenicity and allergic events that is intrinsic to the product in near real-time as part of the active surveillance of subjects vaccinated with 3Fluart vaccine containing influenza virus strains recommended for the 2019/2020 seasonal epidemics in accordance with the Summary of Product Characteristics.

Study Design

Non-interventional study design
Cohort
Other

Non-interventional study design, other
Intensive monitoring schemes

Study drug and medical condition

Name of medicine, other
3Fluart suspension for injection (influenza vaccine, whole virion, inactivated, adjuvanted)

Population studied

Short description of the study population
The study participant with 3Fluart flu vaccine vaccinated according to the instructions for use persons (both men and women) designed minimal and its maximum number is between the following values: one hundred (100) - one hundred and twenty (120) children aged 3-12, one hundred (100) – one hundred and twenty (120) adolescents aged 13-17, one hundred and fifty (150) – one hundred and eighty (180) adults aged 18-65, one hundred and fifty (150) - one hundred and eighty (180) over 65 years of age elderly person in order to total minimum five hundred (500), maximum six hundred (600) test subject's evaluable data must be available.
Participation in the investigation is Hungarian and European Union is done in accordance with regulations and practice.

Age groups
Children (2 to < 12 years)
Adolescents (12 to < 18 years)
Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects
600

Study design details

Data analysis plan
The assessment of safety and tolerability will be primarily based on the occurrence rates of adverse reactions. The occurrence rates of adverse reactions will be summarized by SOC

(System Organ Class) and PT (Preferred Term) and compared to what was already known or expected with 3Fluart vaccine as follows: Evaluation of the occurrence of AEIs and other AEs in vaccinated subjects participating in the study. Occurrence rate of each AE will be presented by age group and severity. Rapid detection of any clinically significant change compared to what was known or expected with the previous vaccine compositions in the frequency and severity of ARs in vaccinated subjects participating in the study. Comparison will be performed between ARs of the study and ARs observed in the last post-authorization safety study performed with 3Fluart influenza vaccine, further, between ARs of the study and with those defined in the SmPC of 3Fluart influenza vaccine.

Documents

Study, other information
3Fluart-H-27_Vizsgálati helyszínek, vizsgálatvezet?k felsorolása_v01_20190528.pdf
(530.74 KB)

Data management

Data sources

Data sources (types)
Disease registry
Drug registry
Spontaneous reporting system

Use of a Common Data Model (CDM)

CDM mapping
No

Data quality specifications

Check conformance
Unknown

Check completeness
Unknown

Check stability
Unknown

Check logical consistency
Unknown

Data characterisation

Data characterisation conducted
No